Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20555736 | 1.00 | HTT (0.53) | HTTMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL20555864 | 1.00 | HTT (0.53) | HTTMEN1KMT2AALDH1A1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL29200867 | 0.87 | HTT (0.52) | HTTMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL14917639 | 0.82 | LMNA (0.47) | HTTMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL14926070 | 0.81 | LMNA (0.46) | HTTMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL1058438 | 0.80 | HTT (0.50) | HTTMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL17627055 | 0.80 | HTT (0.55) | HTTMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL14917955 | 0.79 | LMNA (0.44) | HTTMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL2428998 | 0.78 | HTT (0.56) | HTTMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL1008523 | 0.78 | HTT (0.68) | HTTMEN1KMT2AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476643-B | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | 伊莱利利公司 | 2021-06-08 | — | — | CN | disclosed |
| EP-3484875-B1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10344018-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | ELI LILLY AND COMPANY (US) | 2019-07-09 | — | — | US | disclosed |
| US-10344018-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | ELI LILLY AND COMPANY (US) | 2019-07-09 | — | — | US | disclosed |
| US-10323019-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | ELI LILLY AND COMPANY (US) | 2019-06-18 | — | — | US | disclosed |
| US-10323019-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | ELI LILLY AND COMPANY (US) | 2019-06-18 | — | — | US | disclosed |
| US-20190177300-A1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | LILLY CO ELI (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190177300-A1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | LILLY CO ELI (US) | 2019-06-13 | — | — | US | disclosed |
| CN-109476643-A | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | 伊莱利利公司 | 2019-03-15 | — | — | CN | disclosed |
| US-20180325873-A1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | ELI LILLY AND COMPANY | 2018-11-15 | — | — | US | disclosed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| CN-102007116-A | Pyridazinone glucokinase activators | HOFFMANN LA ROCHE | 2011-04-06 | — | — | CN | disclosed |
| EP-2268633-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127544-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177300-A1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | JAK3, JAK2, JAK1 | HTT 4017/4885MEN1 1122/4885KMT2A 1234/4885 |
| US-10344018-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | JAK3, JAK2, JAK1 | HTT 4017/4885MEN1 1122/4885KMT2A 1234/4885 |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | HTT 3381/4885MEN1 3170/4885KMT2A 3040/4885 |
| US-20180325873-A1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | JAK3, JAK2, JAK1 | HTT 4017/4885MEN1 1122/4885KMT2A 1234/4885 |
| US-10323019-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | JAK3, JAK2, JAK1 | HTT 4017/4885MEN1 1122/4885KMT2A 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.